AnaptysBio, Inc.

NASDAQ:ANAB

Biotechnology

Healthcare
$47.40 -1.88%

-$1.07 today

Market cap
$1.41B
Beta
0.41
P/E (TTM)
-59.7
EPS (TTM)
-$0.93
52W Low $11.40High $72.36

Volume 0.51M

Average 0.76M

Income Statement

Follow revenue through to earnings.

Revenue

$234.60M

FY 2025 · Annual

+157.0% YoY

Operating Income

$47.90M

FY 2025 · Annual

Net Income

-$13.23M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.18M10.29M17.16M91.28M234.6M
Cost of Revenue98.5M88.8M132.28M163.84M2.42M
Gross Profit(35.32M)(78.51M)(115.13M)(72.56M)232.18M
Gross Margin-55.9%-763.2%-671.0%-79.5%99.0%
Research & Development98.5M88.8M139.62M163.84M135.97M
Selling, General & Admin21.49M36.64M41.95M42.39M50.74M
Operating Expenses21.49M36.64M49.29M42.39M184.28M
Depreciation & Amortization2.09M2.34M652K2.4M2.42M
EBITDA(55.71M)(105.26M)(156.42M)(92.74M)69.25M
EBITDA Margin-88.2%-1023.2%-911.7%-101.6%29.5%
Operating Income(56.81M)(115.15M)(164.41M)(114.95M)47.9M
Operating Margin-89.9%-1119.4%-958.3%-125.9%20.4%
Interest Income431K7.55M18.87M19.79M13.5M
Interest Expense1.45M21.11M18.08M50.09M79.89M
Other Income / Expenses(982K)(13.55M)788K(30.28M)(60.96M)
Income Before Tax(57.8M)(128.7M)(163.62M)(145.23M)(13.07M)
Pre-Tax Margin-91.5%-1251.1%-953.7%-159.1%-5.6%
Income Tax Expense024K(4K)3K164K
Net Income(57.8M)(128.72M)(163.62M)(145.23M)(13.23M)
Net Margin-91.5%-1251.3%-953.7%-159.1%-5.6%
EPS (Basic)(2.11)(4.57)(6.08)(5.12)(0.46)
EPS (Diluted)(2.11)(4.57)(6.08)(5.12)(0.46)
Weighted Avg Shares27.43M28.17M26.92M28.38M27.79M
Weighted Avg Shares (Diluted)27.43M28.17M26.92M28.38M31.34M

ANAB Earnings Waterfall · TTM

NASDAQ:ANAB · Revenue to Net Income

Key Ratios

EPS$-1.08
Gross Margin71.6%
Net Margin-78.7%
P/E Ratio1.5
P/S Ratio19.2

Analysis

$232.4M of revenue converted into -$26.8M of net income for the selected period. Gross margin is 71.6% and net margin is -78.7%, showing how much revenue survives after costs and taxes. EPS is $-1.08, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
4Statement of changes in beneficial ownershipOct 2, 2026
10-KT10-KT filingSep 21, 2026
8-KCurrent reportSep 21, 2026

How much revenue does ANAB generate?

AnaptysBio, Inc. (ANAB) reported $234.60M of revenue in fiscal 2025.

Is ANAB profitable?

AnaptysBio, Inc. (ANAB) reported -$13.23M of net income, with a net margin of -5.6%.